Search

Your search keyword '"Al Yung, WK"' showing total 3 results
Start Over Author "Al Yung, WK"
3 results on '"Al Yung, WK"'

1. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas

Author

Boxerman, Jerrold L, Quarles, Chad C, Hu, Leland S, Erickson, Bradley J, Gerstner, Elizabeth R, Smits, Marion, Kaufmann, Timothy J, Barboriak, Daniel P, Huang, Raymond H, Wick, Wolfgang, Weller, Michael, Galanis, Evanthia, Kalpathy-Cramer, Jayashree, Shankar, Lalitha, Jacobs, Paula, Chung, Caroline, van den Bent, Martin J, Chang, Susan, Al Yung, WK, Cloughesy, Timothy F, Wen, Patrick Y, Gilbert, Mark R, Rosen, Bruce R, Ellingson, Benjamin M, Schmainda, Kathleen M, Arons, David F, Kingston, Ann, Sandak, David, Wallace, Max, Musella, Al, and Haynes, Chas

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Biomedical Imaging, Neurosciences, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, Minority Health, Brain Cancer, Algorithms, Brain Neoplasms, Consensus, Contrast Media, Glioma, Humans, Magnetic Resonance Imaging, cerebral blood volume, clinical trial, consensus protocol, DSC-MRI, high-grade glioma, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40-50 ms at 1.5 T, 20-35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.

Published
2020

2. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas

Author

Boxerman, JL, Quarles, CC, Hu, LS, Erickson, BJ, Gerstner, ER, Smits, Marion, Kaufmann, TJ, Barboriak, DP, Huang, RH, Wick, W, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Chung, C, van den Bent, Martin, Chang, Simeng, Al Yung, WK, Cloughesy, TF, Wen, PY, Gilbert, MR, Rosen, BR, Ellingson, BM, Schmainda, KM, Boxerman, JL, Quarles, CC, Hu, LS, Erickson, BJ, Gerstner, ER, Smits, Marion, Kaufmann, TJ, Barboriak, DP, Huang, RH, Wick, W, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Chung, C, van den Bent, Martin, Chang, Simeng, Al Yung, WK, Cloughesy, TF, Wen, PY, Gilbert, MR, Rosen, BR, Ellingson, BM, and Schmainda, KM

Abstract

Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.

Published
2020

3. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Author

Ellingson, BM, Bendszus, M, Boxerman, J, Barboriak, D, Erickson, BJ, Smits, M, Nelson, SJ, Gerstner, E, Alexander, B, Goldmacher, G, Wick, W, Vogelbaum, M, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Pope, WB, Yang, D, Chung, C, Knopp, MV, Cha, S, Van Den Bent, MJ, Chang, S, Al Yung, WK, Cloughesy, TF, Wen, PY, Gilbert, MR, Whitney, A, Sandak, D, Musella, A, Haynes, C, Wallace, M, Arons, DF, and Kingston, A

Abstract

© 2015 The Author(s). A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results